GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » PS Ratio

Prescient Therapeutics (ASX:PTX) PS Ratio

: (As of Today)
View and export this data going back to 1986. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Prescient Therapeutics's share price is A$0.057. Prescient Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Hence, Prescient Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Prescient Therapeutics's PS Ratio or its related term are showing as below:

ASX:PTX's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.15
* Ranked among companies with meaningful PS Ratio only.

Prescient Therapeutics's Revenue per Sharefor the six months ended in Dec. 2023 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

During the past 13 years, Prescient Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -19.00% per year. The lowest was -19.00% per year. And the median was -19.00% per year.

Back to Basics: PS Ratio


Prescient Therapeutics PS Ratio Historical Data

The historical data trend for Prescient Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Prescient Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Prescient Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prescient Therapeutics PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's PS Ratio falls into.



Prescient Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Prescient Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.057/0
=

Prescient Therapeutics's Share Price of today is A$0.057.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prescient Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Prescient Therapeutics  (ASX:PTX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Prescient Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Prescient Therapeutics (ASX:PTX) Business Description

Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines